Human Microglial Precursor Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining human microglial precursor cells are limited by the availability of primary cell lines in small quantities and immortalized cell lines with altered cytokine profiles, which are not suitable for large-scale research or therapeutic applications.
Innovation Solution
A method involving the differentiation of neural precursor cells from human pluripotent stem cells into microglial precursor cells using insulin or insulin-like growth factors, followed by expansion with GM-CSF, and isolation of CD45-positive cells to obtain high-quality microglial precursor cells in large quantities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If primary microglial cells are isolated from brains or mixed glial cultures, then high purity microglial cells are obtained, but the quantity is very limited
Solution Approach 1:
The patent creates a copy of microglial cells by differentiating them from human pluripotent stem cells (hPSCs) through a defined protocol. Instead of isolating limited primary microglia from brain tissue, the invention generates microglial cells in vitro from stem cells, which can be expanded indefinitely while maintaining microglial characteristics and function
Solution Approach 2:
The patent performs preliminary differentiation of hPSCs into microglial precursor cells before expansion. The protocol includes pre-differentiation steps using specific growth factors (insulin/IGF, GM-CSF) to generate microglial precursors that can then be expanded to large quantities while maintaining purity through selective growth conditions
2Productivity
If immortalized microglial cell lines are used, then unlimited cell expansion is achieved, but the cytokine profile is altered
Solution Approach 1:
Instead of using immortalized cell lines that require genetic transformation (which alters cytokine profiles), the patent uses short-lived but genetically unmodified microglial cells derived from hPSCs. These cells can be continuously generated from stem cells without immortalization, maintaining their native cytokine profile while providing sufficient quantities for research
Solution Approach 2:
The patent changes the culture parameters (growth factors, medium composition, differentiation conditions) to generate microglial cells with authentic cytokine profiles. By optimizing insulin/IGF and GM-CSF concentrations and differentiation protocols, the invention produces cells that maintain physiological cytokine secretion patterns unlike immortalized lines
3Reliability
If human primary microglia are obtained from patients or autopsy brains, then authentic human microglial cells are obtained, but the availability is very limited
Solution Approach 1:
The patent creates authentic human microglial cells by differentiating them from human pluripotent stem cells, providing a renewable source that copies the characteristics of primary human microglia without requiring brain tissue donation. This copying approach maintains authenticity while enabling unlimited production
Solution Approach 2:
The invention establishes a self-sustaining system where hPSCs continuously differentiate into microglial cells through defined protocols. The stem cells serve as a self-renewing source that automatically replenishes microglial populations without requiring external tissue samples, enabling continuous production for research and therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the production of high-quality human microglial precursor cells that can be amplified and maintained for extended periods, enabling sufficient cell numbers for research and potential therapeutic applications, such as in neurodegenerative disease treatments.
Implementation Method 1
differentiating the cell population comprising neural precursor cells into microglial precursor cells by culturing in medium comprising a growth factor selected from the group consisting of insulin and insulin-like growth factors
Implementation Method 2
expanding and enriching microglial precursor cells in medium comprising a growth factor selected from the group consisting of insulin and insulin-like growth factors and 10 to 150 ng/ml GM-CSF
Implementation Method 3
isolating microglial precursor cells comprising CD45-positive cells
Implementation Method 4
a purified population of microglial cells can be obtained using density gradients and flow cytometry sorting
Data Source
AI summary
A method for obtaining human microglial precursor cells, comprising: (a) providing a cell population comprising neural precursor cells, wherein the cell population is obtainable from embryoid bodies differentiated from human pluripotent stem cells; (b) differentiating the cell population comprising neural precursor cells into microglial precursor cells by culturing in medium comprising a growth factor selected from the group consisting of insulin and insulin-like growth factors; (c) expanding and enriching microglial precursor cells in medium comprising a growth factor selected from the group consisting of insulin and insulin-like growth factors and 10 to 150 ng/ml GM-CSF; and (d) isolating microglial precursor cells comprising CD45-positive cells.